Skip to main content
SpringerLink
Log in

Use of pegylated recombinant filgrastim (Pegfilgrastim) in patients with acute myeloid leukemia: pharmacokinetics and impact on leukocyte recovery

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Dombret H, Chastang C, Fenaux P, Reiffers J, Bordessoule D, Bouabdallah R et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med 1995; 332: 1678–1683.

    Article  CAS  Google Scholar 

  2. Heil G, Hoelzer D, Sanz MA, Lechner K, Noens L, Szer J et al. Long-term survival data from a phase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia 2006; 20: 404–409.

    Article  CAS  Google Scholar 

  3. Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T et al. Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 1990; 323: 871–877.

    Article  CAS  Google Scholar 

  4. Kern W, Aul C, Maschmeyer G, Kuse R, Kerkhoff A, Grote-Metke A et al. Granulocyte colony-stimulating factor shortens duration of critical neutropenia and prolongs disease-free survival after sequential high-dose cytosine arabinoside and mitoxantrone (S-HAM) salvage therapy for refractory and relapsed acute myeloid leukaemia. German AML Cooperative Group. Ann Hematol 1998; 77: 115–122.

    Article  CAS  Google Scholar 

  5. Johnston E, Crawford J, Blackwell S, Bjurstrom T, Lockbaum P, Roskos L et al. Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. J Clin Oncol 2000; 18: 2522–2528.

    Article  CAS  Google Scholar 

  6. Yang BB, Kido A, Shibata A . Serum pegfilgrastim concentrations during recovery of absolute neutrophil count in patients with cancer receiving pegfilgrastim after chemotherapy. Pharmacotherapy 2007; 27: 1387–1393.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine III, University Hospital Munich, Campus Grosshadern, Marchioninistr, Munich, Germany

    M Fiegl, W Hiddemann & J Braess

Authors
  1. M Fiegl
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W Hiddemann
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J Braess
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the AML Cooperative-Group

Corresponding author

Correspondence to J Braess.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fiegl, M., Hiddemann, W., Braess, J. et al. Use of pegylated recombinant filgrastim (Pegfilgrastim) in patients with acute myeloid leukemia: pharmacokinetics and impact on leukocyte recovery. Leukemia 22, 1284–1285 (2008). https://doi.org/10.1038/sj.leu.2405038

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2405038

  • Springer Nature Limited

Search

Navigation